Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)

Barry Singer; Craig Herrman; Derrick Robertson; Idanis Berrios Morales; Sidarth Dasari; Jonathan Calkwood; Mary Hughes; John Scagnelli; Alise Carlson; Theodore L. Brown; Lawrence Goldstick; Gabriel Pardo; Sibyl Wray; Michael Sy; Martin Belkin; Ahmed Obeidat; Emily Riser; Peiqing Qian; Salvatore Napoli; Christopher LaGanke; Peter Sportelli; Hari Miskin; Edward Fox; Chris Rowland; John Foley

doi:10.1212/wnl.0000000000216380

Key Points

The aim is to provide detailed safety information on a new dosing regimen for ublituximab.
Participants included treatment-naïve individuals and those transitioning from other therapies.
The regimen consolidates initial doses of 150 mg and 450 mg into a single infusion of 600 mg.
No specific safety incidents were reported in the abstract.
Tolerability was assessed during the modified dosing regimen.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluates safety of a single 600 mg ublituximab infusion in treatment-naïve multiple sclerosis.

Abstract

To provide comprehensive safety data on consolidating the initial 150 mg and 450 mg doses into a single 600 mg ublituximab infusion in participants with relapsing multiple sclerosis who are treatment-naïve or transitioning from other disease modifying therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Singer et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0561cb https://doi.org/10.1212/wnl.0000000000216380

View at Publisher

Ask AI

Bookmark

Share

Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading